CrisprBits Unveils State-of-the-Art CRISPR Gene Editing Lab in Bengaluru

Takara Bio Acquires Curio Bioscience, Advancing Leadership in Spatial Genomics

Tempus AI Launches FDA-Approved xT CDx for Comprehensive Solid Tumor Profiling

FDA Accepts Eisai’s Biologics License Application for LEQEMBI® Subcutaneous Autoinjector for Alzheimer’s Disease

Paige’s FullFocus™ Digital Pathology Viewer Receives FDA 510(k) Clearance for Expanded Compatibility

Grifols, MJFF Launch Chronos-PD to Identify Early Parkinson’s Biomarkers

Gates Foundation Invests $50M in Tessera’s In Vivo Gene-Editing Therapy for Sickle Cell Disease

GSK Acquires IDRx for $1 Billion to Advance Precision Therapy for GIST

Scipher Medicine and Roivant Partner to Advance Precision Medicine in Rheumatology

Roche Secures FDA Clearance for VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail to Enhance B-Cell Lymphoma Diagnosis

Illumina Launches Pilot Proteomics Program with UK Biobank and Industry Partners

NavDx Test Expands Availability for Enhanced Surveillance in HPV+ Anal Cancer Patients

QIAGEN Enhances QIAcuity Digital PCR with Expanded Multiplexing Capabilities

Boehringer Ingelheim Licenses Synaffix’s ADC Technology to Advance Cancer Therapies

AIG Hospitals to Launch ₹800 Crore Oncology Centre with South-East Asia’s First Dynamic ARC Proton Therapy

Home
/
update
/
details

CrisprBits Unveils State-of-the-Art CRISPR Gene Editing Lab in Bengaluru

NextEdge Admin

16 Jan 2025

2 min 23 sec

Bengaluru-based biotechnology startup CrisprBits Private Limited has launched a cutting-edge CRISPR gene editing and diagnostics laboratory in the city. The facility boasts advanced infrastructure, including dedicated spaces for lyophilization, cell and tissue culture, bacterial culture, molecular biology research, and cleanroom operations. It features a specialized gene editing section, a tissue culture area for stem cell research, a Laboratory Information Management System (LIMS), and intelligent systems for designing CRISPR guides.

Dr. Vijay Chandru, Co-founder and Director of CrisprBits, remarked, “The launch of our facility marks a significant milestone in delivering affordable, high-quality solutions that positively impact health and the planet.”

Founded in 2020 by BITS Pilani alumni Dr. Vijay Chandru, Sunil Arora, Dr. Rajeev Kohli, Bharat Jobanputra, and Aditya Sarda, CrisprBits is driven by a mission to advance human and environmental well-being through innovation. The company’s women-led scientific team—Vaijayanti Gupta, Reety Arora, and Vandana Hegde—bring expertise in genomics, molecular diagnostics, and gene editing, supported by a distinguished science advisory board.

Initially incubated at CCAMP, CrisprBits has focused on developing rapid molecular diagnostics. The startup plans to launch affordable tests for rare diseases, antimicrobial resistance, and hospital-acquired infections within months. Additionally, it is working on CRISPR applications such as iPSC models for rare diseases and targeted cell-line editing for industrial microbiology.

CrisprBits is among India’s pioneers in leveraging CRISPR technology to create affordable, high-quality life sciences solutions. The company is committed to deep science, ethical standards, and fostering a diverse, exceptional workforce.